Medtronic (NYSE:MDT), in partnership with IBM Watson Health, this week announced commercial availability of its AI-powered Sugar.IQ diabetes management app.

Using artificial intelligence, the Sugar.IQ app evaluates how a user’s blood sugar levels respond to variables such as food intake, insulin dosing and other daily routines.

Get the full story at our sister site, Drug Delivery Business News.